Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market. It also confirmed that its generics unit Sandoz would be spun off by the end of 2023.
This content was published on
3 minutes
Keystone-SDA/jdp
Português
pt
Novartis se concentra em medicamentos de alto valor e mercado americano
During the annual investor day meeting in Basel, Novartis outlined its plan to become what it calls a “pure-play” innovative medicines company after the Sandoz spin-off operation is complete. After a strategic review, Novartis announced in August that it plans to spin off the generics and biosimilars division, which reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but has seen revenue decline in its key market in the US.
Novartis will focus on five disease areas, key technology platforms like cell and gene therapies, and eight brands that it believes have multi-billion-dollar sales potential. Among these are Zolgensma, a $2.1 million gene therapy for spinal muscular atrophy, and Scemblix (asciminib), which was recently approved by US regulators for chronic myeloid leukemia.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The focus on key brands is also intended to help the company boost sales in the US market. In a statement, the company said that it is taking a ‘US-first’ mindset with the aim to “improve competitive positioning” and “become a top-five player in the US by 2027”. Novartis has lagged behind US-based companies such as Pfizer and Johnson & Johnson, ranking tenth in terms of sales in the US market. It also seeks to improve its position in the Chinese market from fifth to third.
This focus on specific high-value brands and the US market, said CEO Vas Narasimhan, is part of an aim to “increase value per new molecular entity” from the company’s pipeline. By 2027, the company expects to achieve average annual sales growth of 4%.
Since Narasimhan took over the CEO post in 2018, Novartis has been shedding parts of its business. It sold its consumer healthcare unit to GSK and spun off its eyecare division Alcon into a separate entity in 2019.
In April Novartis announced a major restructuring to focus on “innovative medicines” – combining its pharmaceutical and oncology divisions. This led the company to shed 7% of its workforce globally. In Switzerland, it said it would cut 10% of its workforce, which means 1,400 jobs will disappear, many of which are in management positions.
In August, the company said it planned to sell off the Sandoz generics unit, which is the last name of the pre-Novartis era, which goes back more than 100 years to the chemical dye industry in Basel. On Thursday, the company confirmed that Sandoz will be spun off by the end of 2023.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
Science alliance warns against Swiss government’s cost-cutting plans
This content was published on
An alliance of research and science institutions have warned of dire consequences if the Swiss government goes ahead with its austerity package.
Accidents during leisure time on the rise in Switzerland
This content was published on
IN 2024 more people had accidents during leisure time than in the previous year. Some 26% of all sports accidents happened playing football.
This content was published on
Apple's iPhones have gained further market share in Switzerland. Around half of all smartphone owners used a model from the US tech giant last year.
Switzerland receives poor marks in fight against public sector corruption
This content was published on
Switzerland is not improving in the fight against corruption according to the Corruption Perceptions Index published by Transparency International.
Swiss army identifies gaps in civil aircraft collision warning system
This content was published on
The Cyber-Defence Campus of the Swiss defence ministry has found two vulnerabilities in the collision warning system for civil aviation.
Can Novartis’s sustainability-linked bond make good on its promises?
This content was published on
Novartis’s sustainability-linked bond was a world first for the pharmaceutical industry. But will it improve access to medicine?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.